By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Global Blood Therapeutics 

400 E. Jamie Court
Suite 101
South San Francisco  California  94080  U.S.A.
Phone: 650-741-7700 Fax: n/a


SEARCH JOBS

Global Blood Therapeutics is developing novel, orally-available therapeutics designed to change the treatment paradigm for chronic blood diseases. The Company is addressing severe, non-malignant blood-based diseases for which there are currently no effective cures and only extremely limited therapeutic options.

The current standard of care treats the symptoms during acute episodes; however, the underlying pathology of the disease causes progressive damage to the body. Global Blood Therapeutics is focused on the critical need for therapeutics that address the causes of blood diseases, not just the symptoms.

Global Blood Therapeutics’ extensive drug discovery capabilities — combining world-class medicinal chemistry with deep expertise in blood biology — are driving its product pipeline of mechanism-based therapeutics.

The Company has built a pipeline of preclinical programs focused on several blood diseases. Its lead program is in sickle cell disease, a global health challenge with very limited treatment options and none that address the underlying cause of the disease. The Company’s pipeline also includes a novel therapeutic for hereditary angioedema.

Global Blood Therapeutics is a private Company led by an experienced management team with a track record of four successful drug approvals and more than 30 investigational new drug applications. Backed by Third Rock Ventures, the Company was founded in 2012 with a $40.7 million Series A financing.


Key Statistics


Email: info@globalbloodtx.com
Ownership: Public

Web Site: Global Blood Therapeutics
Employees: n/a
Symbol: GBT
 



Industry
Biotechnology






Company News
Global Blood Therapeutics (GBT) Announces New Data Supporting Ongoing Clinical Development Of GBT440 In Adolescents With Sickle Cell Disease 6/23/2017 10:34:50 AM
Global Blood Therapeutics (GBT) Reports Recent Business Progress And Provides First Quarter 2017 Financial Results 5/2/2017 11:08:50 AM
Global Blood Therapeutics (GBT) Reports Recent Business Progress And Fourth Quarter And Year-End 2016 Financial Results 3/14/2017 11:01:37 AM
Global Blood Therapeutics (GBT) Announces Closing Of Public Offering Of Common Stock Including Full Exercise Of Option To Purchase Additional Shares 2/28/2017 8:51:09 AM
Global Blood Therapeutics (GBT) Announces Proposed Public Offering Of Common Stock 2/22/2017 11:05:23 AM
Global Blood Therapeutics (GBT) Prices A $125.0 Million Upsized Common Stock Public Offering 2/22/2017 11:03:51 AM
Global Blood Therapeutics (GBT) Announces Initiation Of Phase I Trial To Evaluate The Physiologic Effects Of GBT440 In Healthy Volunteers Under Hypoxemic Conditions 2/17/2017 9:06:27 AM
Global Blood Therapeutics (GBT) Announces Publication Of Paper Describing Discovery Of GBT440 In American Chemical Society Medicinal Chemistry Letters 2/14/2017 11:08:27 AM
Global Blood Therapeutics (GBT) Release: Company Announces Enrollment Of First Patient In Phase III HOPE Study In Sickle Cell Disease 1/18/2017 7:03:09 AM
Global Blood Therapeutics (GBT) Added To NASDAQ Biotechnology Index 12/16/2016 8:47:23 AM
123456
//-->